Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5054733 | 0.84 | CDC25B (0.63) | CDC25BKDM4ETDP1SMN1; SMN2KMT2A | |
| SCHEMBL29596725 | 0.84 | CDC25B (0.63) | CDC25BKDM4ETDP1SMN1; SMN2KMT2A | |
| SCHEMBL271358 | 0.82 | CDC25B (0.52) | CDC25BKDM4ETDP1SMN1; SMN2KMT2A | |
| SCHEMBL27901682 | 0.82 | CDC25B (0.52) | CDC25BKDM4ETDP1SMN1; SMN2KMT2A | |
| SCHEMBL9661958 | 0.81 | PKM (0.60) | CDC25BKDM4ETDP1PKMPOLB | |
| SCHEMBL306689 | 0.81 | CDC25B (0.50) | CDC25BKDM4ETDP1SMN1; SMN2KMT2A | |
| Water SCHEMBL9003956 | 0.81 | CDC25B (0.50) | CDC25BKDM4ETDP1SMN1; SMN2KMT2A | |
| SCHEMBL1040659 | 0.81 | CDC25B (0.50) | CDC25BKDM4ETDP1SMN1; SMN2KMT2A | |
| Ammonia Solution, Strong SCHEMBL5165167 | 0.81 | CDC25B (0.50) | CDC25BKDM4ETDP1SMN1; SMN2KMT2A | |
| Ammonia Solution, Strong SCHEMBL8767660 | 0.81 | CDC25B (0.50) | CDC25BKDM4ETDP1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108430981-B | Process for preparing 1,1, 3-trioxo-1, 2-benzothiazole-6-carboxamides | 阿达玛阿甘股份有限公司 | 2022-05-10 | — | — | CN | claimed |
| EP-3397620-B1 | PROCESS FOR PREPARING 1.1.3-TRIOXO-1.2-BENZOTHIAZOLE-6-CARBOXAMIDE | ADAMA AGAN LTD (IL) | 2020-11-25 | — | — | EP | claimed |
| US-10633352-B2 | Process for preparing 1,1,3-trioxo-1,2-benzothiazole-6-carboxamide | ADAMA AGAN LTD. (IL) | 2020-04-28 | — | — | US | claimed |
| US-20190002419-A1 | PROCESS FOR PREPARING 1,1,3-TRIOXO-1,2-BENZOTHIAZOLE-6-CARBOXAMIDE | ADAMA AGAN LTD. (IL) | 2019-01-03 | — | — | US | claimed |
| EP-3397620-A1 | PROCESS FOR PREPARING 1.1.3-TRIOXO-1.2-BENZOTHIAZOLE-6-CARBOXAMIDE | Adama Agan Ltd. (IL) | 2018-11-07 | — | — | EP | claimed |
| WO-2017115134-A1 | PROCESS FOR PREPARING 1.1.3-TRIOXO-1.2-BENZOTHIAZOLE-6-CARBOXAMIDE | ADAMA AGAN LTD. (IL) | 2017-07-06 | — | — | WO | claimed |
| WO-2023176049-A1 | COMPOSITE REVERSE OSMOSIS MEMBRANE AND PRODUCTION METHOD THEREFOR | 日東電工株式会社 | 2023-09-21 | — | — | WO | disclosed |
| WO-2023176048-A1 | COMPOSITE REVERSE OSMOSIS MEMBRANE AND PRODUCTION METHOD THEREFOR | 日東電工株式会社 | 2023-09-21 | — | — | WO | disclosed |
| CN-108430981-B | Process for preparing 1,1, 3-trioxo-1, 2-benzothiazole-6-carboxamides | 阿达玛阿甘股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-108430981-B | Process for preparing 1,1, 3-trioxo-1, 2-benzothiazole-6-carboxamides | 阿达玛阿甘股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| EP-3096751-B1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-01-06 | — | — | EP | disclosed |
| EP-3397620-B1 | PROCESS FOR PREPARING 1.1.3-TRIOXO-1.2-BENZOTHIAZOLE-6-CARBOXAMIDE | ADAMA AGAN LTD (IL) | 2020-11-25 | — | — | EP | disclosed |
| US-10633352-B2 | Process for preparing 1,1,3-trioxo-1,2-benzothiazole-6-carboxamide | ADAMA AGAN LTD. (IL) | 2020-04-28 | — | — | US | disclosed |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2016-11-17 | — | — | US | disclosed |
| CN-105916499-A | 12-epi-pleuromutilins | 纳布里瓦治疗股份公司 | 2016-08-31 | — | — | CN | disclosed |
| WO-2015110481-A1 | 12-EPI-PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2015-07-30 | — | — | WO | disclosed |
| US-6228808-B1 | BROAD SPECTRUM PRE-EMERGENCE OR POST-EMERGENCE HERBICIDES | HOECHST SCHERING AGREVO GMBH (DE) | 2001-05-08 | — | — | US | disclosed |
| EP-0027906-B1 | PROCESS FOR PREPARING SULPHON AMIDES | BAYER AG (DE) | 1983-05-25 | — | — | EP | disclosed |
| EP-0027906-A1 | Process for preparing sulphon amides | BAYER AG (DE) | 1981-05-06 | — | — | EP | disclosed |
| US-4060549-A | Process for preparing sulfonic acid fluorides | BAYER AKTIENGESELLSCHAFT (DT) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633352-B2 | Process for preparing 1,1,3-trioxo-1,2-benzothiazole-6-carboxamide | SAT1, H1-0, H1-2 | CDC25B 3324/4885KDM4E 1117/4885TDP1 1903/4885 |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | MLN, TCF12, PLEC | CDC25B 4310/4885KDM4E 3574/4885TDP1 4382/4885 |
| US-20190002419-A1 | PROCESS FOR PREPARING 1,1,3-TRIOXO-1,2-BENZOTHIAZOLE-6-CARBOXAMIDE | SAT1, H1-0, H1-2 | CDC25B 3324/4885KDM4E 1117/4885TDP1 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.